Literature DB >> 26260493

Brain connectomics predict response to treatment in social anxiety disorder.

S Whitfield-Gabrieli1,2, S S Ghosh1,3, A Nieto-Castanon1,2,4, Z Saygin2, O Doehrmann1, X J Chai1,2, G O Reynolds1, S G Hofmann5, M H Pollack6, J D E Gabrieli1,2.   

Abstract

We asked whether brain connectomics can predict response to treatment for a neuropsychiatric disorder better than conventional clinical measures. Pre-treatment resting-state brain functional connectivity and diffusion-weighted structural connectivity were measured in 38 patients with social anxiety disorder (SAD) to predict subsequent treatment response to cognitive behavioral therapy (CBT). We used a priori bilateral anatomical amygdala seed-driven resting connectivity and probabilistic tractography of the right inferior longitudinal fasciculus together with a data-driven multivoxel pattern analysis of whole-brain resting-state connectivity before treatment to predict improvement in social anxiety after CBT. Each connectomic measure improved the prediction of individuals' treatment outcomes significantly better than a clinical measure of initial severity, and combining the multimodal connectomics yielded a fivefold improvement in predicting treatment response. Generalization of the findings was supported by leave-one-out cross-validation. After dividing patients into better or worse responders, logistic regression of connectomic predictors and initial severity combined with leave-one-out cross-validation yielded a categorical prediction of clinical improvement with 81% accuracy, 84% sensitivity and 78% specificity. Connectomics of the human brain, measured by widely available imaging methods, may provide brain-based biomarkers (neuromarkers) supporting precision medicine that better guide patients with neuropsychiatric diseases to optimal available treatments, and thus translate basic neuroimaging into medical practice.

Entities:  

Mesh:

Year:  2015        PMID: 26260493     DOI: 10.1038/mp.2015.109

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  45 in total

1.  Selective aberrant functional connectivity of resting state networks in social anxiety disorder.

Authors:  Wei Liao; Huafu Chen; Yuan Feng; Dante Mantini; Claudio Gentili; Zhengyong Pan; Jurong Ding; Xujun Duan; Changjian Qiu; Su Lui; Qiyong Gong; Wei Zhang
Journal:  Neuroimage       Date:  2010-05-11       Impact factor: 6.556

2.  Puzzlingly High Correlations in fMRI Studies of Emotion, Personality, and Social Cognition.

Authors:  Edward Vul; Christine Harris; Piotr Winkielman; Harold Pashler
Journal:  Perspect Psychol Sci       Date:  2009-05

3.  Social phobia. Comorbidity and morbidity in an epidemiologic sample.

Authors:  F R Schneier; J Johnson; C D Hornig; M R Liebowitz; M M Weissman
Journal:  Arch Gen Psychiatry       Date:  1992-04

4.  Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication.

Authors:  Ronald C Kessler; Patricia Berglund; Olga Demler; Robert Jin; Kathleen R Merikangas; Ellen E Walters
Journal:  Arch Gen Psychiatry       Date:  2005-06

5.  Age at onset of alcohol use and its association with DSM-IV alcohol abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey.

Authors:  B F Grant; D A Dawson
Journal:  J Subst Abuse       Date:  1997

6.  Disability and quality of life in social phobia: epidemiologic findings.

Authors:  M B Stein; Y M Kean
Journal:  Am J Psychiatry       Date:  2000-10       Impact factor: 18.112

7.  A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder.

Authors:  Carlos Blanco; Richard G Heimberg; Franklin R Schneier; David M Fresco; Henian Chen; Cynthia L Turk; Donna Vermes; Brigette A Erwin; Andrew B Schmidt; Harlan R Juster; Raphael Campeas; Michael R Liebowitz
Journal:  Arch Gen Psychiatry       Date:  2010-03

8.  Brain regions related to fear extinction in obsessive-compulsive disorder and its relation to exposure therapy outcome: a morphometric study.

Authors:  M A Fullana; N Cardoner; P Alonso; M Subirà; C López-Solà; J Pujol; C Segalàs; E Real; M Bossa; E Zacur; I Martínez-Zalacaín; A Bulbena; J M Menchón; S Olmos; C Soriano-Mas
Journal:  Psychol Med       Date:  2013-06-18       Impact factor: 7.723

9.  Fluoxetine, comprehensive cognitive behavioral therapy, and placebo in generalized social phobia.

Authors:  Jonathan R T Davidson; Edna B Foa; Jonathan D Huppert; Francis J Keefe; Martin E Franklin; Jill S Compton; Ning Zhao; Kathryn M Connor; Thomas R Lynch; Kishore M Gadde
Journal:  Arch Gen Psychiatry       Date:  2004-10

10.  Neural substrates of treatment response to cognitive-behavioral therapy in panic disorder with agoraphobia.

Authors:  Ulrike Lueken; Benjamin Straube; Carsten Konrad; Hans-Ulrich Wittchen; Andreas Ströhle; André Wittmann; Bettina Pfleiderer; Christina Uhlmann; Volker Arolt; Andreas Jansen; Tilo Kircher
Journal:  Am J Psychiatry       Date:  2013-11       Impact factor: 18.112

View more
  63 in total

Review 1.  Psychiatric Illnesses as Oscillatory Connectomopathies.

Authors:  Sophia Vinogradov; Alexander Herman
Journal:  Neuropsychopharmacology       Date:  2016-01       Impact factor: 7.853

Review 2.  The Original Social Network: White Matter and Social Cognition.

Authors:  Yin Wang; Ingrid R Olson
Journal:  Trends Cogn Sci       Date:  2018-04-05       Impact factor: 20.229

3.  Cerebellar Neural Circuits Involving Executive Control Network Predict Response to Group Cognitive Behavior Therapy in Social Anxiety Disorder.

Authors:  Yajing Meng; Yan Zhang; Xiaojing Nie; Zhengjia Ren; Hongru Zhu; Yuchen Li; Su Lui; Qiyong Gong; Changjian Qiu; Wei Zhang
Journal:  Cerebellum       Date:  2017-06       Impact factor: 3.847

4.  Pattern of structural brain changes in social anxiety disorder after cognitive behavioral group therapy: a longitudinal multimodal MRI study.

Authors:  V R Steiger; A B Brühl; S Weidt; A Delsignore; M Rufer; L Jäncke; U Herwig; J Hänggi
Journal:  Mol Psychiatry       Date:  2016-12-06       Impact factor: 15.992

5.  Electrocortical Reactivity During Self-referential Processing in Female Youth With Borderline Personality Disorder.

Authors:  Randy P Auerbach; Naomi Tarlow; Erin Bondy; Jeremy G Stewart; Blaise Aguirre; Cynthia Kaplan; Wenhui Yang; Diego A Pizzagalli
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2016-07

Review 6.  Toward Addiction Prediction: An Overview of Cross-Validated Predictive Modeling Findings and Considerations for Future Neuroimaging Research.

Authors:  Sarah W Yip; Brian Kiluk; Dustin Scheinost
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2019-11-12

7.  Multivariate resting-state functional connectivity predicts response to cognitive behavioral therapy in obsessive-compulsive disorder.

Authors:  Nicco Reggente; Teena D Moody; Francesca Morfini; Courtney Sheen; Jesse Rissman; Joseph O'Neill; Jamie D Feusner
Journal:  Proc Natl Acad Sci U S A       Date:  2018-02-12       Impact factor: 11.205

8.  Resting-State Brain Connectivity Predicts Weight Loss and Cognitive Control of Eating Behavior After Vertical Sleeve Gastrectomy.

Authors:  Hilâl Cerit; Paul Davidson; Taryn Hye; Priyanka Moondra; Florina Haimovici; Stephanie Sogg; Scott Shikora; Jill M Goldstein; A Eden Evins; Susan Whitfield-Gabrieli; Luke E Stoeckel; Laura M Holsen
Journal:  Obesity (Silver Spring)       Date:  2019-11       Impact factor: 5.002

9.  Neural connectivity during affect labeling predicts treatment response to psychological therapies for social anxiety disorder.

Authors:  Katherine S Young; Richard T LeBeau; Andrea N Niles; Kean J Hsu; Lisa J Burklund; Bita Mesri; Darby Saxbe; Matthew D Lieberman; Michelle G Craske
Journal:  J Affect Disord       Date:  2018-08-18       Impact factor: 4.839

10.  Connectome-Based Prediction of Cocaine Abstinence.

Authors:  Sarah W Yip; Dustin Scheinost; Marc N Potenza; Kathleen M Carroll
Journal:  Am J Psychiatry       Date:  2019-01-04       Impact factor: 18.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.